150 related articles for article (PubMed ID: 22623292)
1. Network analysis of reverse phase protein expression data: characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16).
York H; Kornblau SM; Qutub AA
Proteomics; 2012 Jul; 12(13):2084-93. PubMed ID: 22623292
[TBL] [Abstract][Full Text] [Related]
2. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
3. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.
Ruvolo PP; Hu CW; Qiu Y; Ruvolo VR; Go RL; Hubner SE; Coombes KR; Andreeff M; Qutub AA; Kornblau SM
EBioMedicine; 2019 Jun; 44():126-137. PubMed ID: 31105032
[TBL] [Abstract][Full Text] [Related]
4. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBFβ-MYH11.
Kanagal-Shamanna R; Zhao W; Vadhan-Raj S; Nguyen MH; Fernandez MH; Medeiros LJ; Bueso-Ramos CE
Int J Environ Res Public Health; 2012 Aug; 9(8):2788-800. PubMed ID: 23066397
[TBL] [Abstract][Full Text] [Related]
6. Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia.
Elo LL; Karjalainen R; Ohman T; Hintsanen P; Nyman TA; Heckman CA; Aittokallio T
Proteomics; 2014 Nov; 14(21-22):2443-53. PubMed ID: 25211154
[TBL] [Abstract][Full Text] [Related]
7. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome Profiling of Pediatric Core Binding Factor AML.
Hsu CH; Nguyen C; Yan C; Ries RE; Chen QR; Hu Y; Ostronoff F; Stirewalt DL; Komatsoulis G; Levy S; Meerzaman D; Meshinchi S
PLoS One; 2015; 10(9):e0138782. PubMed ID: 26397705
[TBL] [Abstract][Full Text] [Related]
10. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
11. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
12. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
Marcucci G; Caligiuri MA; Bloomfield CD
Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
[TBL] [Abstract][Full Text] [Related]
13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
14. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Haferlach T; Kohlmann A; Klein HU; Ruckert C; Dugas M; Williams PM; Kern W; Schnittger S; Bacher U; Löffler H; Haferlach C
Leukemia; 2009 May; 23(5):934-43. PubMed ID: 19194466
[TBL] [Abstract][Full Text] [Related]
15. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities.
Jakovic L; Bogdanovic A; Djordjevic V; Dencic-Fekete M; Kraguljac-Kurtovic N; Knezevic V; Tosic N; Pavlovic S; Terzic T
Leuk Res; 2018 Dec; 75():23-28. PubMed ID: 30445236
[TBL] [Abstract][Full Text] [Related]
18. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
19. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Huang JC; Basu SK; Zhao X; Chien S; Fang M; Oehler VG; Appelbaum FR; Becker PS
Blood Cancer J; 2015 Apr; 5(4):e302. PubMed ID: 25860293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
